Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>As Published</td>
<td><a href="http://dx.doi.org/10.1073/pnas.1412631111">http://dx.doi.org/10.1073/pnas.1412631111</a></td>
</tr>
<tr>
<td>Publisher</td>
<td>National Academy of Sciences (U.S.)</td>
</tr>
<tr>
<td>Version</td>
<td>Final published version</td>
</tr>
<tr>
<td>Accessed</td>
<td>Wed Feb 27 13:00:40 EST 2019</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://hdl.handle.net/1721.1/95798">http://hdl.handle.net/1721.1/95798</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>Article is made available in accordance with the publisher’s policy and may be subject to US copyright law. Please refer to the publisher’s site for terms of use.</td>
</tr>
<tr>
<td>Detailed Terms</td>
<td></td>
</tr>
</tbody>
</table>
Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems

Amir Shlomai,a,1 Robert E. Schwartz,b,c,1 Vyasa Ramanana,c,1 Ankit Bhattach,a Ype P. de Jong,b,d Sangeeta N. Bhatiad,e,f,g,h,1,2,3, and Charles M. Ricea,2,3

Laboratory of Virology and Infectious Disease, Center for the Study of Hepatitis C, The Rockefeller University, New York, NY 10065; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115; Department of Health Sciences and Technology, Department of Electrical Engineering and Computer Science, Koch Institute for Integrative Cancer Research, and Howard Hughes Medical Institute, Massachusetts Institute of Technology, Cambridge, MA 02139; Division of Gastroenterology and Hepatology, Department of Medicine, Center for the Study of Hepatitis C, Weill Cornell Medical College, New York, NY 10065; and Broad Institute of MIT and Harvard, Cambridge, MA 02139

Contributed by Charles M. Rice, July 10, 2014 (sent for review June 3, 2014)

Hepatitis B virus (HBV) chronically infects 400 million people worldwide and is a leading driver of end-stage liver disease and liver cancer. Research into the biology and treatment of HBV requires an in vitro cell-culture system that supports the infection of human hepatocytes, and accurately recapitulates virus–host interactions. Here, we report that micropatterned cocultures of primary human hepatocytes with stromal cells (MPCCs) reliably support productive HBV infection, and infection can be enhanced by blocking elements of the hepatocyte innate immune response associated with the induction of IFN-stimulated genes. MPCCs maintain productive, lasting infection and represent a facile platform for studying virus–host interactions and for developing antiviral interventions. Hepatocytes obtained from different human donors vary dramatically in their permissiveness to HBV infection, suggesting that factors—such as divergence in genetic susceptibility to infection—may influence infection in vitro. To establish a complementary, renewable system on an isogenic background in which candidate genetics can be interrogated, we show that inducible pluripotent stem cells differentiated into hepatocyte-like cells (iHeps) support HBV infection that can also be enhanced by blocking interferon-stimulated gene induction. Notably, the emergence of the capacity to support HBV transcriptional activity and initial permissiveness for infection are marked by distinct stages of iHep differentiation, suggesting that infection of iHeps can be used both to study HBV, and conversely to assess the degree of iHep differentiation. Our work demonstrates the utility of these infectious systems for studying HBV biology and the virus’ interactions with host hepatocyte genetics and physiology.

HBV persistence | innate immunity | viral hepatitis

Hepatitis B virus (HBV) is a small 3.2-kb DNA virus that selectively infects hepatocytes in the human liver (1). The global disease burden is large, with ~400 million people chronically infected worldwide, of whom about one-third will develop severe HBV-related complications, such as cirrhosis and liver cancer. Lifelong treatment is often required because of the stable nature of viral episomal DNA, known as covalently closed circular DNA (cccDNA), which maintains basal levels in infected cell nuclei even upon nucleos(t)ide inhibitor treatment. To date, HBV research has been hampered by a distinct lack of robust infectious model systems that both support productive HBV infection and accurately mimic virus–host interactions. Recently, the bile acid pump sodium taurocholate cotransporting polypeptide (NTCP) has been identified as a receptor for both HBV and hepatitis D virus (2), and overexpression of NTCP in hepatoma cell lines renders them susceptible to HBV infection. However, hepatoma cells are known to be defective in many cellular pathways implicated in the innate immune response (3, 4), metabolism (5), and cell proliferation (6), which may contribute to published contradictory evidence regarding the extent to which HBV activates the innate immune response, and the importance of this response in curtailing infection (for a review, see ref. 7).

As the sole host cell infected by HBV in vivo, primary human hepatocytes represent the gold-standard for studying HBV interactions with the host. Prior studies have shown that primary human hepatocytes support HBV infection, although infection is usually not robust even upon supplementation of cell-culture medium with dimethyl sulfoxide (8) or polyethylene glycol (9). Moreover, primary human hepatocytes rapidly lose their hepatic phenotype shortly after isolation from the in vivo microenvironment (10, 11). We have previously developed a miniaturized system in which primary hepatocytes are organized in micropatterned colonies and surrounded by supportive stromal cells, providing hepatocytes with the necessary homotypic and heterotypic cell–cell interactions to promote long-term maintenance of their hepatic function (12). This micropatterned coculture (MPCC) system maintains hepatocyte phenotype and function over several weeks and has been shown to support robust infection with hepatitis C virus (HCV) and Plasmodium...
falciparum and vivax malaria (13, 14). We hypothesized that this system would be ideal for modeling HBV infection in vitro.

Beyond its potential utility for assessing virus–host interactions, studying the role of host factors in the MPCC system is complicated by limited availability and variability between donor hepatocytes. As a complementary approach that enables more facile genetic manipulation on an untransformed and isogenic hepatocyte background, we also sought to establish robust HBV infection in induced pluripotent stem cell (iPSC)-derived hepatocyte-like cells (iHeps) (15, 16). These cells have demonstrated their utility for modeling inherited metabolic disorders (17), incorporating genetic manipulations (18), and supporting infection with HCV (19–21). During iHep generation, the progression of differentiation is characterized by the sequential emergence of various hepatocyte-specific host factors known to play a role in the HBV life cycle, such as the transcription factor HNF4α and the nuclear receptor RXR (22). We show that permissiveness to HBV infection likewise progresses in a differentiation stage-specific manner. Thus, in this paper we use a system of stabilized primary hepatocytes for disease modeling to establish HBV infection in vitro and explore the use of directed differentiation of iPSCs to demonstrate that they serve as a suitable host population for the study of HBV and host–virus interactions.

Results

Micropatterned Human Hepatocytes Stably Express the HBV Receptor for Weeks in Culture. It has been hypothesized that primary human hepatocytes lose their permissiveness to HBV infection because of down-regulation of NTCP receptor expression upon isolation and subsequent culture (2). Our MPCCs of primary human hepatocytes and stromal fibroblasts (J2-3T3 fibroblasts, or J2s) maintain hepatocyte functions as well as polarity and promote the accurate localization of membrane proteins to hepatocytes’ basolateral and apical domains (12). Although many distinct hepatocyte culture models have been explored in the literature, a telling control to probe the importance of tissue microarchitecture is seeding similar cellular constituents in a random configuration (random coculture, RCC) (Fig. 1A). NTCP was readily detected on the plasma membrane by immunostaining of hepatocytes in MPCCs (Fig. 1B), whereas the NTCP level at 18 d postplating was drastically reduced in RCCs (Fig. 1C–D). Because viral spread is dependent upon consistent expression of the entry receptor, we analyzed NTCP levels over a course of 14 d, and found that NTCP protein and mRNA levels remained stable over time (Fig. S1A). These results establish the capacity of the MPCC format to maintain expression of the HBV receptor, NTCP, in vitro.

Fig. 1. HBV infection in micropatterned primary human hepatocytes is augmented by innate immune inhibition. (A) MPCC vs. RCC schematic. Hepatocytes in pink, fibroblasts in purple. (B) NTCP immunostaining: white circle marks hepatocyte island boundary. (Scale bar, 100 μm.) (C) NTCP Western blot. (D) NTCP quantitative RT-PCR (qRT-PCR; mean ± SEM, n = 3). (E) Schematic of viral life-cycle readouts used. (F, Left panels) ELISA for HBsAg, expressed as a mean ± SEM (n = 3), secreted into supernatant between 14 and 16 dpi; (Center) HBV 3.5-kb mRNA expression (one cell pellet per condition) at 16 dpi; (Right) Copies of cccDNA at 16 dpi, expressed as an average of biological duplicates ± range. (G) HBc immunostaining of MPCCs at the indicated days postinfection. Isotype-matched negative control shown. (Scale bars, 50 μm.) (H) Time course of HBV infection in MPCCs. (Left panels) HBsAg and HBeAg levels (average of triplicates) in supernatant; (Center) cccDNA levels; (Right panels) qRT-PCR for HBV 3.5-kb mRNA and total mRNA. Expression relative to DMSO-treated samples 7 dpi, one pellet per condition per experiment, verified across independent experiments. Dotted lines: limit of quantification (qPCR), cut-off (ELISA).
MPCCs Support Productive HBV Infection. Given the importance of the MPCC format for maintaining expression of the HBV receptor as well as other hepatocyte functions (Fig. S1 B and C), we next investigated whether MPCCs support HBV infection. We assayed various viral life-cycle stages, including viral gene expression, reflected by HBV surface antigen (HBsAg) secretion and 3.5-kb mRNA (the main HBV transcript) production, and the presence of the viral transcription template cccDNA, considered a hallmark of productive infection (Fig. 1E). We found that HBV derived from human infectious serum infects human hepatocytes more efficiently in MPCCs than RCCs (Fig. 1F). Furthermore, MPCCs support productive infection throughout the culture period of nearly 3 wk, based on immunostaining for HBV core (HBc) protein (Fig. 1G).

Based on previous data that the innate immune response can restrict HCV infection in hepatocytes (23), we explored pretreatment of MPCCs or RCCs with a broad-spectrum Janus kinase (JAK) inhibitor (JAKI), known to interfere with a major pathway of the innate immune axis by dampening expression of IFN-stimulated genes (ISGs) (24), in an attempt to elicit enhanced HBV replication efficiency. With the addition of JAKI, we observed more robust HBV infection in MPCCs (Fig. 1H) and detected cccDNA almost exclusively in this format (Fig. 1F, Right). Augmentation of HBV infection was also observed upon introduction of an inhibitor of TANK-binding kinase 1 (TBK1), an upstream activator of the IFN response pathway, although JAKI was more efficient in maintaining cccDNA following infection (Fig. S2). Collectively, these results suggest that the MPCC format supports the maintenance of productive infection over time in primary human hepatocytes, and that inhibition of major pathways of the hepatocyte innate immune response enhances infection in this system.

Temporal Expression of ISGs Following HBV Infection. In response to intracellular pattern sensors, an innate immune pathway typically activates a set of ISGs, leading to autocrine/paracrine signaling by interferons. Based on our observation that addition of a JAK pathway inhibitor improved HBV infection in MPCCs, we hypothesized that the innate immune response may induce antiviral ISGs, at least in culture. To assay for this response, we incubated MPCCs with HBV infectious serum and analyzed the relative expression of type I IFNs, IFN-α, and IFN-β, as well as two genes implicated in type III IFN response, over the next 16 d (Fig. 2, Left). Both IFN-α and IFN-β were induced mainly late during the course of infection, although a modest induction (>two-fold) was detected as early as 12 h postinfection. The expression of a variety of ISGs implicated in antiviral responses were also detected following HBV infection, with a range of kinetic patterns, including several that function as sensors and transducers of these pathways (Fig. 2, Center), and a selection of antiviral effectors (Fig. 2, Right). Consistent with our hypothesis, we found that blunting the innate immune response with JAK inhibition blocked the expression of many downstream ISGs but had no significant effect on the expression of either IFN-α or IFN-β, which are regulated upstream of JAK-STAT1 signaling. We note that some exhibit a biphasic elevation over time, possibly representing reinfection events or expression in response to the emergence of later stage viral components. Importantly, ISG induction was dependent on productive HBV infection, because pretreatment of MPCCs with the HBV inhibitor entecavir largely abolished the induction of most early- and late-stage interferons and downstream ISGs (Fig. S3A).

Interestingly, although productive infection could be clearly detected in NTCP-expressing HepG2 hepatoma cells, as evidenced by production of HBV 3.5-kb mRNA (Fig. S3B, Left), no significant ISG induction was observed in these cells compared with HBV nonpermissive HepG2 cells (Fig. S3B, Right). These data suggest that either HBV sensors or key transducers in this sensing pathway are defective in hepatoma cells, highlighting a distinct opportunity of the MPCC system in terms of its potential for studying virus-host interactions in HBV infection.

MPCCs Offer the Potential to Study Antiviral Candidates. Following the demonstration that the MPCC format can support HBV infection, we asked whether the platform could be applied for use as an anti-HBV drug-testing tool. As proof-of-principle, we incubated MPCCs with HBV-infected serum with or without concomitant treatment with the HBV reverse-transcriptase inhibitor entecavir, or an alternate antiviral, IFN-β. The addition of prophylactic entecavir or IFN-β to MPCCs abrogated HBV infection, as indicated by a sharp decrease in the secretion of both HBV DNA and HBsAg into the medium over time (Fig. 3A). Consistent with these findings, levels of cellular 3.5-kb mRNA and cccDNA were also dramatically reduced in infected cells pretreated with IFN-β or with entecavir, as long as 21 d postinfection (dpi) (Fig. S4).

Having established that MPCCs can successfully model prophylactic drug protection against HBV, we assayed their potential utility to model a more clinically relevant regimen by starting treatment with IFN-β or entecavir 7 d after establishing HBV infection. Both treatments significantly reduced HBV DNA secretion into the medium by preinfected MPCCs, indicating an efficient inhibition of HBV replication (Fig. 3B). In contrast, only IFN-β, but not entecavir, abolished the levels of 3.5-kb mRNA and cccDNA observed at 16 dpi (9 d after initiating drug treatment), consistent with published differences in the capacity of reverse-transcriptase inhibitors versus interferons to promote cccDNA elimination (25). Collectively, these results demonstrate that the MPCC system can serve as a platform for studying the efficacy and mechanism of action of diverse antiviral agents, and has the potential to be expanded to a medium-to-high throughput drug-discovery tool (13, 26).
To establish a viable drug testing platform, it is essential to identify a source of reproducibly infectible hepatocytes. The advent of cryopreserved human hepatocytes partially achieves this goal, in terms of offering a uniform donor source. To examine the importance of host variability in HBV infection of MPCCs, we used MPCCs seeded with hepatocytes derived from different hepatic donors. Differentiation of many of the same ISGs that were observed in HBV-infected MPCCs (Fig. S6C) were also detected in day 20 differentiated iHeps, largely independent of JAK inhibition. The viral life cycle. Analysis performed at 16 dpi revealed signs of productive infection in fully differentiated iHeps (day 20 of differentiation), as evidenced by 3.5-kb mRNA expression, HBsAg secretion, and cccDNA accumulation (Fig. 4A–C). To examine both the specificity and kinetics of HBV infection of day 20 iHeps, we incubated cells with HBV infectious serum with or without JAKi and the antiviral drug entecavir. Response by treating the cells with JAK inhibitor generally resulted in increased HBsAg secretion, as well as cccDNA production, although in some donors (such as HD2), even JAK inhibition was unable to promote the production of detectable levels of cccDNA. Furthermore, the interdonor variation in infection levels did not correlate with other established biomarkers of hepatocyte function (Fig. S5). Collectively, these results suggest that MPCCs support HBV infection in a hepatocyte donor-dependent manner. Although technical factors implicated in hepatocyte isolation and cryopreservation may play a role, it is also possible that a divergence in genetically determined host factors may underlie this variation.

**iPSC-Derived iHeps as a Candidate HBV Host in Vitro.** To overcome the variability in HBV permissiveness observed among donors of primary human hepatocytes, we considered options for generating a physiologically relevant in vitro system on an isogenic background. iPSCs are renewable, can be derived from a single donor, and repeatedly differentiated into iHeps that share features of human hepatocytes (15, 16, 26) (Fig. S6D). To ascertain whether iHeps might be permissive to HBV infection, we first investigated the expression kinetics of NTCP during the course of i Hep differentiation. Using immunostaining, we observed that although NTCP was largely detectable on day 15, it was readily detectable 3 d later and increased throughout the remainder of the differentiation protocol (Fig. S6F, Left). Consistent with the protein-expression findings, quantitative analysis of NTCP mRNA levels also showed a gradual increase throughout differentiation, although the level achieved in day 20 differentiated iHeps remained less than that observed in cryopreserved primary adult hepatocytes (Fig. S6F, Right).

In addition to the dependence on an entry receptor, iHeps must also exhibit the capacity to support HBV transcription to support replication. Thus, we assessed the earliest stage at which differentiating iHeps achieved this milestone by transfecting them with an HBV luciferase reporter construct (Fig. S6C). Although the liver-enriched transcription factor HNF-4α, central to the activation of the HBV transcriptional program (27), is expressed early during iHep differentiation (22, 28) (Fig. S6D), HBV transcriptional activity was not detected until day 18, after which it continued to rise (Fig. S6C).

**iHeps Support Productive HBV Infection During Late Stages of Differentiation.** To investigate whether iPSC-derived iHeps are permissive to productive HBV infection, we incubated differentiating iPSCs with HBV infectious serum and assayed for markers of the viral life cycle. Analysis performed at 16 dpi revealed signs of productive infection in fully differentiated iHeps (day 20 of differentiation), but not in cells infected at earlier stages of differentiation, as evidenced by 3.5-kb mRNA expression, HBsAg secretion, and cccDNA accumulation (Fig. 4A–C). To examine both the specificity and kinetics of HBV infection of day 20 iHeps, we incubated cells with HBV infectious serum with or without JAKi and the antiviral drug entecavir. When analyzed over a 3-wk period, only JAKi-treated iHeps maintained significant secretion of HBsAg over time, in contrast to a rapid loss of HBsAg produced by vehicle-treated or entecavir-treated cells (Fig. 4D).}

**Hepatic Donors That Share a Differentiated Phenotype in Vitro Exhibiting Variable HBV Permissiveness.** To establish a viable drug testing platform, it is essential to identify a source of reproducibly infectible hepatocytes. The advent of cryopreserved human hepatocytes partially achieves this goal, in terms of offering a uniform donor source. To examine the importance of host variability in HBV infection of MPCCs, we used MPCCs seeded with hepatocytes derived from different hepatic donors (HD) (Table S1) and incubated them with patient-derived HBV infectious serum. Analyzing markers of productive infection revealed a wide variation between donors, with hepatic donor 4 (HD4) showing the most robust HBsAg production (Fig. 3C) and cccDNA formation (Fig. 3D). Notably, blocking the type I IFN response by treating the cells with JAK inhibitor generally resulted in increased HBsAg secretion, as well as cccDNA production, although in some donors (such as HD2), even JAK inhibition was unable to promote the production of detectable levels of cccDNA. Furthermore, the interdonor variation in infection levels did not correlate with other established biomarkers of hepatocyte function (Fig. S5). Collectively, these results suggest that MPCCs support HBV infection in a hepatocyte donor-dependent manner. Although technical factors implicated in hepatocyte isolation and cryopreservation may play a role, it is also possible that a divergence in genetically determined host factors may underlie this variation.

**Fig. 3.** MPCCs as a platform for anti-HBV drug studies. (A) MPCCs treated with DMSO or JAKi, with or without entecavir or IFN-γ, were incubated with HBV infectious serum for 24 h, followed by continued drug treatment every 2 d. Collected supernatants were analyzed for HBV DNA after 3 wk (Left), and for secreted HBsAg at the indicated time points (Right); results are expressed as a mean ± SEM, n = 3. (B) HBV-infected MPCCs treated with JAKi were dosed with either IFN-γ or entecavir from 7 to 16 dpi, when cell pellets were analyzed for 3.5-kb mRNA expression relative to nonantiviral treated cells (one cell pellet per condition, verified across multiple experiments; Left) and for cccDNA, expressed as an average (per cell pellet) of duplicates ± range (Right). Also at 16 dpi, medium (last changed at 14 dpi) was analyzed for secreted HBV DNA, expressed as a mean ± SEM (n = 3) (Center). (C and D) JAKi or DMSO-treated MPCCs bearing primary human hepatocytes from different donors were incubated with HBV infectious serum and assayed at 16 dpi for HBsAg, expressed as average of duplicates, and cccDNA quantification, total copies per cell pellet. Dotted lines indicate limit of quantification (qPCR) or cut-off (ELISA).

---

4 of 6 | www.pnas.org/cgi/doi/10.1073/pnas.1412631111

Shlomai et al.
HBV infection of iHeps is drug-sensitive and differentiation-dependent. (A–C) iPSCs were differentiated in a stepwise fashion, treated with JAKi, and incubated with HBV infectious serum upon treatment at the indicated days of the differentiation protocol. (A) At 16 dpi, HBV 3.5-kb mRNA was quantified by qRT-PCR, shown relative to DMSO-treated cells infected at day 10 of differentiation, and expressed as the mean ± SEM across two separate experiments. (B) Also at 16 dpi, medium (last changed at 14 dpi) was analyzed for secreted HBsAg (mean ± SEM, n = 3). (C) Agarose gel separation of amplified cccDNA products (16 dpi) on a single gel with high- (+) and low- (−) expression positive controls (size mismatch because of slight curvature between distant lanes). (D) Differentiated iHeps (day 20 of differentiation) treated as indicated were incubated with HBV infectious serum at day 10 of differentiation, and expressed as a mean ± SEM across two separate experiments. (E) Also at 16 dpi, medium (last changed at 14 dpi) was analyzed for secreted HBsAg (mean ± SEM, n = 3). (F) ISG mRNA expression by qRT-PCR of HBV-infected iHeps at 16 dpi, normalized to the expression of HBV infected cells at day 7 of differentiation.

Our observation that innate immune activation restricts HBV infection is consistent with studies showing that HBV can be cleared from the liver in a cytokine-mediated, noncytotoxic manner (25, 32), and that HBV replication is significantly reduced in chimpanzees chronically infected with HCV because of the induction of the type I IFN response (33). In contrast to the robust induction of ISGs in HBV-infected MPCCs, and to a lesser extent in iHeps, no ISG response was observed in HBV-permissive cells. By leveraging inherent strengths of the iHep system to identify candidate essential host factors that confer HBV sensitivity, we can also leverage inherent strengths of the iHep system to identify candidate essential host factors that confer HBV sensitivity.

Discussion

In this study, we report HBV infection in two complementary patient-derived hepatocyte systems in which infection is limited by an innate immune response, and demonstrate the utility of these systems for studying virus–host interactions. The establishment of two complementary HBV model systems represents an opportunity to tackle questions regarding major components of the viral entry process and viral life cycle, including host factors underlying establishment and persistence of a nuclear cccDNA pool, the key viral reservoir that leaves patients susceptible to viral reactivation (29).

The MPCC system uses micropatterned primary human hepatocytes cocultured with stromal fibroblasts, a format that ensures the prolonged viability and functionality of these delicate cells (12). By comparing the HBV permissiveness of MPCCs to that of cocultured cells seeded in a random format, we show that the patterning provided by the MPCC format is essential to maintaining productive infection for up to 3 wk. An advantage of the MPCC system is its facility for interrogating the identity of host factors responsible for the observed permissiveness, in that cryopreserved donor cells that exhibit comparable hepatocyte functions in culture but disparate permissiveness to HBV infection can be subjected to systematic molecular analysis. In this manner, candidate host-factor pathways and drug-targeting strategies may be explored in vitro.

We can also leverage inherent strengths of the iHep system to identify candidate essential host factors that confer HBV sensitivity. In the differentiating populations, we observe that HBV transcriptional activity increases over time, and can be overlaid with the stepwise process of hepatocyte-specific factor acquisition. Thus far, our differentiation time course data tracking both NTCP expression and HBV promoter-enhancer element-driven luciferase expression demonstrate that the up-regulation of both entry factors and other transcription-related host factors are essential for successful infection by HBV. We observe a tipping point for permissiveness at around days 18–20 of the iHep differentiation process, corresponding to a switch from a hepatoblast-like phenotype to one resembling fetal hepatocytes. A comparison of populations on either side of this time point may identify candidate pathways, to be filtered based on findings from the MPCC system, and interrogated via directed mutagenesis or selective generation of iPSC lines from desired genotypes. In addition, the stage-specific acquisition of permissiveness to hepatotropic pathogens may offer a novel method for assessing the relative success of candidate in vitro differentiation protocols.

One important suite of host factors consists of the proteins involved in the hepatocyte innate immune response, the role of which in restricting HBV infection has been difficult to pin down (7). Much of this debate has resulted from deficiencies in the model systems used for HBV studies, because commonly used hepatoma cell lines possess well-documented defects in innate immune sensing and signal transduction (3, 4). In our systems, the establishment of productive and long-lasting infection was aided by inhibiting the innate immune response with inhibitors of the JAK family or the signaling intermediate TBK1. However, our data show that JAK inhibition boosted infection much more in MPCCs than in day 20 differentiated iHeps, as evidenced by the similar levels of viral replication achieved with and without JAK inhibition in differentiated iHeps (Fig. 4). This difference may be caused by the weaker induction of ISGs observed in MPCCs than in day 20 differentiated iHeps, as evidenced by the similar levels of viral replication achieved with and without JAK inhibition in differentiated iHeps (Fig. 4). This difference may be caused by the weaker induction of ISGs observed in MPCCs than in day 20 differentiated iHeps, as evidenced by the similar levels of viral replication achieved with and without JAK inhibition in differentiated iHeps (Fig. 4). This difference may be caused by the weaker induction of ISGs observed in MPCCs than in day 20 differentiated iHeps, as evidenced by the similar levels of viral replication achieved with and without JAK inhibition in differentiated iHeps (Fig. 4). This difference may be caused by the weaker induction of ISGs observed in MPCCs than in day 20 differentiated iHeps, as evidenced by the similar levels of viral replication achieved with and without JAK inhibition in differentiated iHeps (Fig. 4). This difference may be caused by the weaker induction of ISGs observed in MPCCs than in day 20 differentiated iHeps, as evidenced by the similar levels of viral replication achieved with and without JAK inhibition in differentiated iHeps (Fig. 4). This difference may be caused by the weaker induction of ISGs observed in MPCCs than in day 20 differentiated iHeps, as evidenced by the similar levels of viral replication achieved with and without JAK inhibition in differentiated iHeps (Fig. 4). This difference may be caused by the weaker induction of ISGs observed in MPCCs than in day 20 differentiated iHeps, as evidenced by the similar levels of viral replication achieved with and without JAK inhibition in differentiated iHeps (Fig. 4). This difference may be caused by the weaker induction of ISGs observed in MPCCs than in day 20 differentiated iHeps, as evidenced by the similar levels of viral replication achieved with and without JAK inhibition in differentiated iHeps (Fig. 4). This difference may be caused by the weaker induction of ISGs observed in MPCCs than in day 20 differentiated iHeps, as evidenced by the similar levels of viral replication achieved with and without JAK inhibition in differentiated iHeps (Fig. 4). This difference may be caused by the weaker induction of ISGs observed in MPCCs than in day 20 differentiated iHeps, as evidenced by the similar levels of viral replication achieved with and without JAK inhibition in differentiated iHeps (Fig. 4). This difference may be caused by the weaker induction of ISGs observed in MPCCs than in day 20 differentiated iHeps, as evidenced by the similar levels of viral replication achieved with and without JAK inhibition in differentiated iHeps (Fig. 4). This difference may be caused by the weaker induction of ISGs observed in MPCCs than in day 20 differentiated iHeps, as evidenced by the similar levels of viral replication achieved with and without JAK inhibition in differentiated iHeps (Fig. 4).
HepG2 cells overexpressing NTCP. This finding emphasizes the advantage of both MPCCs and iPHePS over hepatoma cell lines and traditional hepatocyte culture systems in the analysis of virus–host interactions, in particular innate immune responses. A similar induction of the type I IFN response accompanied by up-regulation of ISGs was previously observed in HBV-permissive HepaRG cells, but not in HepG2 cells upon induction of a baculovirus expressing HBV (34). However, even in HepaRG cells, the bipotential nature of the cells suggests an immature state in which the innate immune axis may not be fully developed. Similarly, our observation that iPHePS display more modest, differentiation stage-dependent ISG induction relative to MPCCs, may be explained by the finding that the innate immune axis matures in concert with the hepatic phenotype of differentiating iPHePS (35). Thus, our results support the model that the innate immune system plays a role in HBV infection and suggests that HBV may be less of a “stealth virus” than previously thought (36).

Notably, in the MPCC platform, we observed that a constant fraction of around 25% of the cells were HBc-positive between 7 and 19 d postinfection. This absence of apparent viral spread raises the possibility that viral production is not robust enough to support reinfection, or that the rate of new infection is offset by viral clearance from other cells. In addition, given the prolonged maintenance of normal hepatocyte function in the MPCC system, it is not clear why levels of HBV surface antigen and DNA secretion drop precipitously by 21 dpi. One possible explanation is that a gradual reduction in host factors essential to the viral transcription/replication machinery induces an eventual block at the level of gene expression or replication. The observation that the ccDNA level remains relatively stable even after the sharp decline in the viral gene expression and replication raises the intriguing possibility that these kinetics represent a switch from a more acute stage of infection to one that is more chronic and low-level.

In summary, we show that MPCCs and pluripotent stem cell-derived iPHePS are both permissive to and support productive HBV infection. We envision these platforms to be complementary, each with their own advantages, and also each with the capacity to inform further optimization of the other. Thus, the combination of our HBV infectious systems will open new avenues to more fully characterize the HBV life cycle and its interaction with the host, thereby promoting the identification of potential drug targets for a disease infecting 400 million people globally.

Materials and Methods

The experimental conditions used to generate MPCCs, maintain iPSCs, and differentiate iPHePS have all been previously described (12, 15, 16, 19). For HBV infection of MPCCs and iPHePS, cultures were pretreated for 24 h with dimethyl sulfoxide [0.01% (vol/vol)], JAKi (1 μM; EMD Millipore), TBK1 inhibitor (1 μM; EMD Millipore), IFN-β (1,000 U/mL; R&D Systems), or entecavir (120 nM; CytoMagic Chemicals), as indicated, followed by infection with HBV patient plasma. Additional details are described in Supplementary Materials and Methods, including techniques used to assess HBV infection, such as total DNA, ccDNA, RNA analysis, immunofluorescence, and ELISA for HBsAg and HBeAg.

Acknowledgments

We thank H. Fleming for manuscript editing. This study was supported in part by The Center for Basic and Translational Research on Disorders of the Digestive System through the generosity of the Leona M. and Harry B. Helmsley Charitable Trust (A.S.), Skolkovo Institute of Science and Technology Grant 102247 (A.S.), National Institutes of Health Grants U24 AI104341 (to S.N.B. and N.H.), and the National Institutes of Health Grant CA140511 (to G.A.C.). The National Institutes of Health, A.M., and S.N.B. are supported by the National Institute of Diabetes and Digestive and Kidney Diseases (DK88230 to A.M., DK110538 to S.N.B.), and the National Institute of General Medical Sciences (GM115255 to G.A.C.). The work of S.A. was supported by a grant from the Skolkovo Institute of Science and Technology (1228). We thank H. Fleming for manuscript editing.

In summary, we show that MPCCs and pluripotent stem cell-derived iPHePS are both permissive to and support productive HBV infection. We envision these platforms to be complementary, each with their own advantages, and also each with the capacity to inform further optimization of the other. Thus, the combination of our HBV infectious systems will open new avenues to more fully characterize the HBV life cycle and its interaction with the host, thereby promoting the identification of potential drug targets for a disease infecting 400 million people globally.

Materials and Methods

The experimental conditions used to generate MPCCs, maintain iPSCs, and differentiate iPHePS have all been previously described (12, 15, 16, 19). For HBV infection of MPCCs and iPHePS, cultures were pretreated for 24 h with dimethyl sulfoxide [0.01% (vol/vol)], JAKi (1 μM; EMD Millipore), TBK1 inhibitor (1 μM; EMD Millipore), IFN-β (1,000 U/mL; R&D Systems), or entecavir (120 nM; CytoMagic Chemicals), as indicated, followed by infection with HBV patient plasma. Additional details are described in Supplementary Materials and Methods, including techniques used to assess HBV infection, such as total DNA, ccDNA, RNA analysis, immunofluorescence, and ELISA for HBsAg and HBeAg.

Acknowledgments

We thank H. Fleming for manuscript editing. This study was supported in part by The Center for Basic and Translational Research on Disorders of the Digestive System through the generosity of the Leona M. and Harry B. Helmsley Charitable Trust (A.S.), Skolkovo Institute of Science and Technology Grant 102247 (A.S.), National Institutes of Health Grants U24 AI104341 (to S.N.B. and N.H.), and the National Institutes of Health Grant CA140511 (to G.A.C.). The National Institutes of Health, A.M., and S.N.B. are supported by the National Institute of Diabetes and Digestive and Kidney Diseases (DK88230 to A.M., DK110538 to S.N.B.), and the National Institute of General Medical Sciences (GM115255 to G.A.C.). The work of S.A. was supported by a grant from the Skolkovo Institute of Science and Technology (1228). We thank H. Fleming for manuscript editing.

In summary, we show that MPCCs and pluripotent stem cell-derived iPHePS are both permissive to and support productive HBV infection. We envision these platforms to be complementary, each with their own advantages, and also each with the capacity to inform further optimization of the other. Thus, the combination of our HBV infectious systems will open new avenues to more fully characterize the HBV life cycle and its interaction with the host, thereby promoting the identification of potential drug targets for a disease infecting 400 million people globally.

Materials and Methods

The experimental conditions used to generate MPCCs, maintain iPSCs, and differentiate iPHePS have all been previously described (12, 15, 16, 19). For HBV infection of MPCCs and iPHePS, cultures were pretreated for 24 h with dimethyl sulfoxide [0.01% (vol/vol)], JAKi (1 μM; EMD Millipore), TBK1 inhibitor (1 μM; EMD Millipore), IFN-β (1,000 U/mL; R&D Systems), or entecavir (120 nM; CytoMagic Chemicals), as indicated, followed by infection with HBV patient plasma. Additional details are described in Supplementary Materials and Methods, including techniques used to assess HBV infection, such as total DNA, ccDNA, RNA analysis, immunofluorescence, and ELISA for HBsAg and HBeAg.

Acknowledgments

We thank H. Fleming for manuscript editing. This study was supported in part by The Center for Basic and Translational Research on Disorders of the Digestive System through the generosity of the Leona M. and Harry B. Helmsley Charitable Trust (A.S.), Skolkovo Institute of Science and Technology Grant 102247 (A.S.), National Institutes of Health Grants U24 AI104341 (to S.N.B. and N.H.), and the National Institutes of Health Grant CA140511 (to G.A.C.). The National Institutes of Health, A.M., and S.N.B. are supported by the National Institute of Diabetes and Digestive and Kidney Diseases (DK88230 to A.M., DK110538 to S.N.B.), and the National Institute of General Medical Sciences (GM115255 to G.A.C.). The work of S.A. was supported by a grant from the Skolkovo Institute of Science and Technology (1228). We thank H. Fleming for manuscript editing.